|  Sign up!  


Return to Course Listing



CME: Male Osteoporosis Management: Advances in Pharmacotherapy


Program Description / Statement of Need:

In this online CME self-learning program:


Osteoporosis is characterized by low bone mass and deterioration of bone tissues, which leads to an increased risk of skeletal fractures.Although osteoporosis is generally considered as a women’s health issue and often overlooked problem in men,osteoporosis in men is also an important public health issue, and its prevalence is increasing as the general population ages( – rising to 11% in men by age 80. Around 1 to 2 million men in the United States have been estimated to have clinical osteoporosis, and an additional 8 to 13 million men identified to have low bone mass.In sum, 35% of men are considered to have low bone density by age 50, and that number rises to 53% by age 80.(3) These numbers have practical consequences, as the risk of fracture increases with age. Not only are fractures of the vertebrae, hip, and humerus associated with complications that include pain, kyphosis, intra-abdominal compression, impaired gastrointestinal nutrition, depression, loss of mobility and autonomy, and a lower quality of life,but hip fracture in particular is associated a poor prognosis,including a 40% return to prefracture level of independence, 20% rate of long-term care requirements by patients, and the strongest correlation with mortality.





Introduction content: cursory refresher and review of male osteoporosis

  • Epidemiology
  • Defining clinical features
  • Risk factors
  • Statistics
  • Guidance on screening criteria in men: DXA, FRAX
  • Patient cases

Treatment options

  • Goal of treatments
    • A review of present pharmacotherapy; the roles of:
    • RANKL inhibitors
    • Bisphosphonates
    • Parathyroid hormone-related protein analogs
    • Testosterone therapy
    • Barriers to optimal care in male patients with Osteoporosis
  • Investigational therapies
  • Lifestyle factors and risk factor modification



Target Audience:

The following healthcare professionals: primary care physicians and endocrinologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in endocrinology and internal medicine; and any other healthcare professionals with an interest in or who clinically encounter patients with male osteoporosis.

Program Objectives:

By the end of the session the participant will be able to:

    • Apply screening criteria for male osteoporosis to a given patient
    • Describe the criteria for initiation of pharmacotherapy for osteoporosis treatment and prevention and apply them to a patient case
    • Identify present pharmacotherapeutic treatments for management of male osteoporosis, and describe their mechanisms of action and place in therapy
    • Describe investigational pharmacotherapeutic treatments for management of male osteoporosis, and describe their mechanisms of action and likely place in therapy
    • Describe the challenges associated with treating patients with male osteoporosis, focus specifically on the risks (e.g., adverse drug reactions, drug interactions, et cetera) of the agents used to treat and prevent osteoporosis and apply the information in optimizing patient care in a patient case


    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.


    Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.


    ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.





    ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.0 hours (0.1 CEUs) of continuing education.  Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.   Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.  ACPE # 0574-0000-18-020-H01-P.  ACPE Accreditation effective 05/09/18, expires 04/30/2020. This is a Knowledge (K)-type activity.

    Release Date: April 30, 2018
    Expiration Date: April 30, 2020

    Faculty: Maria Skamagas MD

    Faculty Disclosure and Resolution of COI:

    As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.


    Faculty Disclosure: Dr. Skamagas, MD, Assistant Professor, Icahn School of Medicine, New York, NY has no relevant financial disclosures.


    Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP has no relevent financial disclosures.


    Commercial Support Disclosure: This program is supported by an educational grant from AMGEN.

    Additional Courses That Are Related To This Course

    Osteoporosis Management: Advances in Pharmacotherapy

    Chronic Idiopathic Constipation (CIC): Optimizing Pharmacotherapeutic Management Strategies

    Frontiers in the Pharmacotherapeutic Management of Osteoporosis


    Viewing Instructions



    Windows 2000 or above
    Internet Explorer 5.5
    Adobe Acrobat Reader*

    Mac OS 10.2.8
    Adobe Acrobat Reader*
    Internet Explorer is not supported on the Macintosh


    *Required to view Printable PDF Version


    Privacy Policy



    -Read the learning objectives and faculty disclosures above

    -Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.

    -View the on-line program. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.

    -Take the post-test

    -Complete the program evaluation and CME registration. A CE certificate will be emailed to you.

    Perform Pre-Test (optional)
    Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

    Download the Presentation (optional)


    View the online program


    Perform Post-Test

    Complete the Symposium Evaluation and Request CE Certificate

Commercial Support Disclosure: This program is supported by an educational grant from AMGEN.


Your feedback is important to us. Please Contact Us to let us know how to make this site better. Thank you.